文献速递炎症性肠病肝病

临床试验:双倍剂量与标准剂量乙型肝炎疫苗在炎症性肠病中的免疫原性

Clinical Trial: Immunogenicity of Double-Dose Versus Standard-Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2025-11-20

这项随机试验比较了双倍剂量(40 μg)与标准剂量(20 μg)乙型肝炎疫苗在炎症性肠病(IBD)患者中的免疫原性。双倍剂量组在达到充分免疫应答(抗-HBs > 10 IU/L)和有效免疫应答(抗-HBs > 100 IU/L)的比例上均显著高于标准剂量组,尤其在接受免疫抑制治疗的患者中差异明显。结论支持对IBD患者采用双倍剂量策略以优化血清转化。

要点

  • 双倍剂量乙肝疫苗显著提高IBD患者充分免疫应答率(88.4% vs 55.6%,p=0.001)。
  • 双倍剂量也提高有效免疫应答率(69.8% vs 46.7%,p=0.028)。
  • 接受免疫抑制治疗者获益更明显,未接受者差异不显著。

核心结论

  • 双倍剂量乙肝疫苗较标准剂量显著改善IBD患者的充分免疫应答和有效免疫应答。

研究设计与样本

  • 随机对照试验,将IBD患者1:1分配至标准剂量(20 μg)或双倍剂量(40 μg)乙肝疫苗组,于0、1、6个月接种。
  • 共随机45例至标准剂量组、43例至双倍剂量组,第三剂后1个月检测抗-HBs滴度。

主要发现

  • 总体63例(71.6%)达到充分免疫应答(抗-HBs > 10 IU/L),51例(57.9%)达到有效免疫应答(抗-HBs > 100 IU/L)。
  • 双倍剂量组充分免疫应答率88.4% vs 标准剂量组55.6%(p=0.001),有效免疫应答率69.8% vs 46.7%(p=0.028)。
  • 接受免疫抑制治疗者中,双倍剂量组充分免疫应答率87.5% vs 45.2%(p<0.001),有效免疫应答率65.6% vs 35.5%(p=0.017)。
  • 多变量分析中,充分免疫应答的预测因素包括双倍剂量接种(OR 11.63;95%CI 2.63-51.46)和抗TNF药物(OR 0.03;95%CI 0.002-0.6)。
  • 双倍剂量接种与有效免疫应答的更高几率相关(OR 3.52;95%CI 1.04-11.92)。

关键数值与推荐

  • 充分免疫应答定义为抗-HBs滴度 > 10 IU/L,有效免疫应答定义为抗-HBs滴度 > 100 IU/L。

临床怎么用

  • 对于IBD患者,尤其是接受免疫抑制治疗者,可考虑采用双倍剂量乙肝疫苗以优化血清转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunogenic response to hepatitis B virus (HBV) vaccine in patients with inflammatory bowel disease (IBD) is variable and often suboptimal. AIM: To compare the immunogenicity of standard-dose (20 μg) vs. double-dose (40 μg) HBV vaccination in patients with IBD. METHODS: We randomised patients with IBD 1:1 to receive standard- or double-dose HBV vaccine at 0, 1 and 6 months. Anti-HBs titres were measured 1 month after the third dose. The primary outcome was an adequate immune response (AIR; anti-HBs titre > 10 IU/L). Secondary outcomes included an effective immune response (EIR; anti-HBs titre > 100 IU/L) and seroconversion stratified by disease activity. RESULTS: We randomised 45 patients to the standard-dose and 43 to the double-dose. Overall, 63 patients (71.6%) achieved AIR, and 51 (57.9%) achieved EIR. Both AIR (88.4% vs. 55.6%, p = 0.001) and EIR (69.8% vs. 46.7%, p = 0.028) rates were significantly higher with the double-dose. Among patients receiving immunosuppressive therapy, double-dose vaccination demonstrated significantly higher AIR (87.5% vs. 45.2%, p < 0.001) and EIR (65.6% vs. 35.5%, p = 0.017), while differences were not significant in those without immunosuppression. On multivariable analysis, predictors of AIR included double-dose vaccination (odds ratio [OR] 11.63; 95% confidence interval [CI] 2.63-51.46) and anti-TNFs (OR 0.03; 95% CI 0.002-0.6). Double-dose vaccination was also associated with higher odds of achieving EIR (OR 3.52; 95% CI 1.04-11.92). CONCLUSIONS: Double-dose HBV vaccination significantly improved AIR and EIR over standard-dose. These findings support a double-dose strategy to optimize seroconversion in patients with IBD, especially those receiving immunosuppressive therapy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Singh AK, Soni RK, Jearth V, et al. Clinical Trial: Immunogenicity of Double-Dose Versus Standard-Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2025. PMID: 41267335. doi:10.1111/apt.70470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。